Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive.

We believe there is minimal cause for concern with LLY stock, which makes it attractive but highly sensitive to adverse ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

However, analysts believe that such levies would likely have minimal financial repercussions for drug manufacturers due to the high profit margins associated with many medications. Eli Lilly is ...

Eli Lilly and Company ( NYSE:LLY ) just reported healthy earnings but the stock price didn't move much. We think ...

Eli Lilly is still in the early stages of its growth ... And while current shareholders may secure a good profit by selling it today, unless they need the money for other reasons, there's no ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli ...

Eli Lilly & Co. said Thursday that its Type 2 diabetes ... after the company said it expects to generate an adjusted 2025 profit of $22.50 a share to $24 a share in 2025, compared with the FactSet ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.

Eli Lilly is offering vials of its weight-loss drug Zepbound to patients at a discount — but only if they skip their ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...